ClinicalTrials.gg
RecruitingNCT07671079CLIBMUpdated Nov 16, 2026

Closed-loop tES-non-invasive Stimulation

An interventional study of Transcranial low intensity focused ultrasound (FUS) and transcranial electrical stimulation in Closed-loop Brain Stimulation, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of Nottingham · Not applicable, Interventional, and Basic science

Updated Nov 16, 2026Now RecruitingStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The goal of this study is to establish if non-invasive closed-loop neuromodulation is an effective approach to enhance cognitive function in healthy 18-40 years old volunteers. The main questions it aims to answer are:

  • Can closed-loop stimulation increase stimulation effectiveness?
  • Can closed-loop focused ultrasound specifically engage with excitatory or inhibitory neural populations in the target structure as measured through MRS?
  • Can observed stimulation outcomes for FUS be predicted through connectome analysis and computational models of indirect changes?

Researchers will compare different closed-loop options to their open-loop counterpart to see if closed-loop approaches can increase efficacy and reduce the variability of the stimulation compared to open-loop approaches.

Participants will:

  • Answer some questionnaires at the start of the study and after each intervention session.
  • Undertake a MRI scanning session.
  • Undertake one open-loop FUS session.
  • Undertake one tES session.
  • Undertake one closed-loop FUS sessions involving tES and FUS, followed by a MRI scanning
  • Undertake one sham FUS session
  • Attend one visit in person to assess eligibility through questionnaires and one cognitive task
Read the detailed description

Closed-loop approaches may offer greater efficacy and lower variability across individuals compared to current open-loop stimulation approaches, yet they remain a relatively new approach, with no studies evaluating closed-loop transcranial low-intensity focused ultrasound stimulation (FUS) yet.

For this reason, we will collect and evaluate cognitive, biological and metabolic data from healthy participants, before and after closed-loop and open-loop stimulation interventions. This will allow us to compare our proposed closed-loop stimulation approach to stablished non-invasive techniques and to investigate the underlying mechanisms through which FUS can alter brain activity.

For this study, participants will attend multiple visits. To assess eligibility, participants will attend one initial session in-person before the start of the study.

Following safety guidelines, each participant will receive a maximum of two 1-hour MRI scanning sessions in a single week.

This study will be separated into two blocks of stimulation sessions: one block for tACS-FUS, and another block for TI-FUS. Participants will be randomly allocated to receive one of the blocks.

Before the during recruitment, participants will be asked to complete online some baseline questionnaires such as the O-Life inventory, BECK, MAIA, or STAI. Furthermore, full eligibility will be assessed in person.

At the first appointment, participants will have a brain scan at Sir Peter Mansfield Imaging Centre or Queen's Medical Centre, Nottingham, UK. This will help us to apply the brain stimulation to the right part of the participant's brain, as well as obtain baseline functional, metabolic and structural information.

Participants will be randomly allocated to either receive open-loop FUS (FUS with Sham tES), closed-loop FUS (dual FUS-tES), tES with Sham FUS, or double sham FUS-tES, in the second appointment and the other interventions in the subsequent visits for their assigned block. During all stimulation sessions, we will use an AntNeuro neuronavigation system to guide the location of the transducer.

During either of the stimulation visits, participants will have physiological (EEG) and cognitive markers recorded. Some emotional assessments (i.e., through a short STAI) will be performed before and after stimulation. EEG recordings will be conducted before, during and after stimulation on the same day. Rest-state EEG will be recorded pre-stimulation before the start of the cognitive tasks, and post-stimulation after the end of the cognitive tasks.

The participant will then undergo one cognitive assessment, which will consists on a visual working memory task (delayed-spatial-estimation-task). The task involves visual stimuli, with responses recorded via keyboard. The task is designed to take approximately 5-15 minutes to complete on pre and post-stimulation. The duration of the task during stimulation will be adapted to the duration of the stimulation. Following this, participants will receive the allocated intervention.

Participants will have the same physiological and cognitive assessments recorded during the stimulation and after the stimulation has been completed. For the closed-loop stimulation, participants will also undergo an MRI scanning after the stimulation.

The first visit, consisting of brain scan, will be separated by at least 24 hours from the second visit. Subsequent visits will be separated by at least one week from each other.

During each consecutive appointment, participants will be asked about any changes to their eligibility and continued consent.

02

Conditions studied

  • Closed-loop Brain Stimulation

Keywords

  • neuromodulation
  • electrical stimulation
  • transcranial low-intensity focused ultrasound stimulation
  • closed-loop neuromodulation
03

In context

Lead sponsor

University of Nottingham is the lead sponsor of 465 studies on the registry; 80 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is willing and able to give for participation in the study
  • Aged between 18 and 40
  • Good general health
  • Not consume alcohol 48 hours prior study visit
  • Not currently taking any medications (except pills) or if on long-term medication for a non-neurological/non-psychiatric condition (r.g. inhalers) to be considered otherwise healthy and stable with no symptoms
  • Be right handedness

Exclusion criteria

Exclusion Criteria:

  • Inability to complete MRI/FUS/TMS/tES safety questionnaire and / or process.
  • Current or previous diagnosis of a neurological, neurosurgical, psychiatric disorders.
  • Other significant medical condition (specific details to be reviewed by the CI prior to inclusion).
  • Currently pregnant, breast feeding, or on planned pregnancy.
  • Medication intake (such as beta-blocker, , anti-depressants, anti-inflammatory drugs in the last 7d).
  • Medication intake (such as antidepressants, antipsychotics, anti-epileptics, beta blockers, glucocorticoids, anti-inflammatories, benzodiazepines, hypnotics, sedating antihistamines or any illicit substances in the past seven days).
  • Significant use of medication or recreational drugs that affect the nervous system.
  • Excessive consumption of alcohol.
  • Known allergy to any required consumables (such as aquasonic gel).
  • History of anaphylaxis to any substance
  • Have tightly coiled, curly or voluminous texture hair type (e.g., hair type 3, 4, or afro hair).
  • Having skin disease or sensitive skin on or close to the head.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Open-loop transcranial low-intensity FUS

    Transcranial low intensity focused ultrasound stimulation (FUS) with 500kHz transducer for following either the continuous theta burst or intermittent theta burst protocol using the NeuroFus PRO system

    Other: Transcranial low intensity focused ultrasound (FUS) · Procedure: Magnetic Resonance Imaging

  • Experimental
    Closed-loop transcranial low-intensity FUS

    Closed-loop Transcranial Electrical Stimulation by means of tACS or TI delivered through a Digitimer DS5 for brain entrainment phase-locked on peak or trough to transcranial low intensity FUS delivered to dACC through the NeuroFUS PRO system

    Other: Transcranial low intensity focused ultrasound (FUS) · Other: transcranial electrical stimulation · Procedure: Magnetic Resonance Imaging

  • Active comparator
    tES alone

    tACS or TI delivered through a Digitimer DS5 for brain entrainment phase-locked on peak or trough

    Other: transcranial electrical stimulation · Procedure: Magnetic Resonance Imaging

  • Active comparator
    Sham FUS

    FUS delivered to ventricles or FUS and tACS located on head, one of them on or off depending on sham, or active.

    Other: Transcranial low intensity focused ultrasound (FUS) · Procedure: Magnetic Resonance Imaging

Interventions

  • OtherTranscranial low intensity focused ultrasound (FUS)

    Low intensity focused ultrasound stimulation (FUS) with 500kHz transducer for following either the continuous theta burst or intermittent theta burst protocol using the NeuroFus PRO system

    Also known as: LIFU, tFUS, TUS

  • Othertranscranial electrical stimulation

    Transcranial electrical stimulation (by means of transcranial alternating current stimulation (tACS) or non-invasive temporal interference (TI) electrical stimulation) using the DS5 isolated bipolar constant current stimulator together connected to a wave generator and with two electrodes for tACS (TI implementation will be carried out with two DS5 systems, separate wave generators and four electrodes).

    Also known as: tES

  • ProcedureMagnetic Resonance Imaging

    We obtain baseline functional, metabolic and structural information through MRI and MRS scanning

    Also known as: MRI

06

What researchers measure

Primary outcomes

  1. Change from Baseline in EEG Power in Alpha Band (8-12Hz)

    Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation

  2. Change from Baseline in EEG Power in Theta Band (4-7Hz)

    Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation

  3. Change from Baseline in EEG Power in Beta Band (13-30Hz)

    Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation

  4. Change from Baseline in EEG Power in Gamma Band (31-45Hz)

    Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation

  5. Changes from Baseline in EEG-derived spectral power

    Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation

  6. Changes from Baseline in Functional connectivity (e.g., through changes in Phase-locked value (PLV))

    Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation

  7. Average Reaction time (ms) measured from the Visual Working memory task

    Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation

  8. Average Overall accuracy (%) measured from Visual Working Memory task

    Time frame: Baseline to 10 weeks, measured immediately before, during, and immediately after stimulation

  9. Change from Baseline in Target-Region metabolite Concentration measured via Magnetic Resonance Spectroscopy (MRS)

    Time frame: Baseline (Day 1) to immediately after closed-loop post-stimulation intervention

  10. Changes from Baseline in Functional Connectivity calculated from functional Magnetic Resonance Imaging (fMRI)

    Time frame: Baseline (Day 1) to immediately after closed-loop post-stimulation intervention

  11. Changes from Baseline on Structural connectivity metrics derived from multi-shell diffusion MRI (dMRI) tractography

    Time frame: Baseline (Day 1) to immediately after closed-loop post-stimulation intervention

Secondary outcomes

  1. Structured questionnaire assessing adverse effects of the intervention

    Time frame: Immediately after stimulation, 24 hours after stimulation and 1 week after stimulation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Zhai Z, Ren L, Song Z, Xiang Q, Zhuo K, Zhang S, Li X, Zhang Y, Jiao X, Tong S, Sun J, Liu D. The efficacy of low-intensity transcranial ultrasound stimulation on negative symptoms in schizophrenia: A double-blind, randomized sham-controlled study. Brain Stimul. 2023 May-Jun;16(3):790-792. doi: 10.1016/j.brs.2023.04.021. Epub 2023 Apr 29. No abstract available. PubMed 37121354 ↗
  • Sarica C, Nankoo JF, Fomenko A, Grippe TC, Yamamoto K, Samuel N, Milano V, Vetkas A, Darmani G, Cizmeci MN, Lozano AM, Chen R. Human Studies of Transcranial Ultrasound neuromodulation: A systematic review of effectiveness and safety. Brain Stimul. 2022 May-Jun;15(3):737-746. doi: 10.1016/j.brs.2022.05.002. Epub 2022 May 6. PubMed 35533835 ↗
  • Raco V, Bauer R, Tharsan S, Gharabaghi A. Combining TMS and tACS for Closed-Loop Phase-Dependent Modulation of Corticospinal Excitability: A Feasibility Study. Front Cell Neurosci. 2016 May 25;10:143. doi: 10.3389/fncel.2016.00143. eCollection 2016. PubMed 27252625 ↗
  • Briley PM, Boutry C, Webster L, Veniero D, Harvey-Seutcheu C, Jung J, Liddle PF, Morriss R. Intermittent theta burst stimulation with synchronised transcranial alternating current stimulation leads to enhanced frontal theta oscillations and a positive shift in emotional bias. Imaging Neurosci (Camb). 2024 Jan 25;2:imag-2-00073. doi: 10.1162/imag_a_00073. eCollection 2024. PubMed 40800403 ↗
  • Nakazono H, Ogata K, Takeda A, Yamada E, Oka S, Tobimatsu S. A specific phase of transcranial alternating current stimulation at the beta frequency boosts repetitive paired-pulse TMS-induced plasticity. Sci Rep. 2021 Jun 23;11(1):13179. doi: 10.1038/s41598-021-92768-x. PubMed 34162993 ↗
  • Zrenner C, Desideri D, Belardinelli P, Ziemann U. Real-time EEG-defined excitability states determine efficacy of TMS-induced plasticity in human motor cortex. Brain Stimul. 2018 Mar-Apr;11(2):374-389. doi: 10.1016/j.brs.2017.11.016. Epub 2017 Nov 24. PubMed 29191438 ↗
  • Gold JM. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res. 2004 Dec 15;72(1):21-8. doi: 10.1016/j.schres.2004.09.008. PubMed 15531404 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jun 26, 2026
StartEst.
Nov 2026was Sep 2026
Primary completionEst.
Aug 2027
CompletionEst.
Dec 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
University of Nottingham is now Recruiting
Nov 16, 2026
Start date
Sep 2026→Nov 2026
Nov 16, 2026
Documents
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    Documents Study protocol ↗ updated
    University of Nottingham is now Recruiting
    Start date Sep 2026→Nov 2026
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07671079
Responsible party
Marcus Kaiser (Professor of Neuroinformatics, University of Nottingham) — Principal investigator
First posted
Jun 26, 2026
Start date
Nov 2026 (estimated)
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Dr. Falcon Caro
Contact
alicia.falconcaro@nottingham.ac.uk
+44 115 823 2866
Dr. Halls
Contact
Daniel.Halls@nottingham.ac.uk
+44 115 823 2866
Marcus Kaiser, PhD
principal investigator · University of Nottingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion